drugset / Trial / NCT05533411
A Study of Donanemab (LY3002813) in Healthy Chinese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.
Timeline
- Start
- 2022-09-14
- Primary completion
- 2023-01-05
- Completion
- 2023-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donanemab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Donanemab | Monoclonal antibody | 700 mg | Intravenous |
| Subject | Donanemab | Monoclonal antibody | 1400 mg | Intravenous |
Indications
No indication recorded.